International Journal of Drug Policy
Volume 21, Issue 1 , Pages 82-85 , January 2010

Dissolution of a harm reduction track for opiate agonist treatment: Longitudinal impact on treatment retention, substance use and service utilization

Received 27 October 2008 ,Revised 22 January 2009 ,Accepted 27 January 2009.

References 

  1. Alexandre PK, Salome HJ, French MT, Rivers JE, McCoy CB. Consequences and costs of closing a publicly funded methadone maintenance clinic. Social Science Quarterly. 2002;83(2):519–536
  2. Anglin MD, Speckart GR, Booth MW, Ryan TM. Consequences and costs of shutting off methadone. Addictive Behaviors. 1989;14(3):307–326
  3. Beutler LE. Methodology: What are the design issues involved in the defined research priorities?. In:  Onken LS,  Blaine JD editor. Psychotherapy and counseling in the treatment of drug abuse. Rockville, MD: US Department of Health and Human Services; 1990;(Vol. NIDA Research Monograph 104, pp. 105–120)
  4. Britton BM. The privatization of methadone maintenance: Changes in risk behavior associated with cost related detoxification. Addiction Research. 1994;2(2):171–181
  5. Calsyn DA, DeMarco FJ, Saxon AJ, Sloan KL, Gibbon K. Evaluation of a minimal services treatment track as an alternative to discharge for non-compliant patients in opioid substitution treatment. American Journal of Public Health. 2003;93:1086–1088
  6. CSAT. (2005). Medication-assisted treatment for opioid addiction in opioid treatment programs. Rockville, MD: Substance Abuse and Mental Health Services Administration.
  7. Drummer OH. Recent trends in narcotic deaths. Therapeutic Drug Monitoring. 2005;27(6):738–740
  8. Fuller BE, Rieckmann TR, McCarty DJ, Ringor-Carty R, Kennard S. Elimination of methadone benefits in the Oregon health plan and its effects on patients. Psychiatric Services. 2006;57(5):686–691
  9. Grella CE, Anglin MD, Rawson R, Crowley R, Hasson A. What happens when a demonstration project ends. Journal of Substance Abuse Treatment. 1996;13(3):249–256
  10. Griffith JD, Rowan-Szal GA, Roark RR, Simpson DD. Contingency management in outpatient methadone treatment: A meta-analysis. Drug and Alcohol Dependence. 2000;58:55–66
  11. Knight KR, Rosenbaum M, Irwin J, Kelley MS, Wenger L, Washburn A. Involuntary versus voluntary detoxification from methadone maintenance treatment: The importance of choice. Addiction Research. 1996;3(4):351–362
  12. Mark TL, Woody GE, Juday T, Kleber HD. The economic costs of heroin addiction in the United States. Drug and Alcohol Dependence. 2001;61(2):195–206
  13. Marlatt GA. Harm reduction: Pragmatic strategies for managing high-risk behaviors. New York: Guilford Press; 1998;
  14. McLellan AT, Chalk M, Bartlett J. Outcomes, performance, and quality—what's the difference?. Journal of Substance Abuse Treatment. 2007;32:331–340
  15. O’Toole TP, Pollini R, Gray P, Jones t, Bigelow G, Ford DE. Factors identifying high-frequency and low-frequency health service utilization among substance using adults. Journal of Substance Abuse Treatment. 2007;33:51–59
  16. Peirce JM, Petry NM, Stitzer ML, Blaine J, Kolodner K, et al. Lower-cost incentives increase stimulant abstinence in methadone maintenance community treatment: Results of the national drug abuse treatment clinical trials network multi-site study. Archives of General Psychiatry. 2006;63(2):201–208
  17. Petry NM. A comprehensive guide to the application of contingency management procedures in clinical settings. Drug and Alcohol Dependence. 2000;58:9–25
  18. Rosenbaum M, Washburn A, Knight KR, Kelley MS, Irwin J. Treatment as harm reduction, defunding as harm maximization: The case of methadone maintenance. Journal of Psychoactive Drugs. 1996;28(3):241–249
  19. Silverman K, Wong CJ, Higgins ST, Brooner RK, Montoya ID, et al. Increasing opioid abstinence through voucher-based reinforcement therapy. Drug and Alcohol Dependence. 1996;41:157–165
  20. Stitzer ML, Bigelow GE, Lawrence C, Cohen J, D’Lugoff B, Hawthorne J. Medication take-home as a reinforcer in a methadone maintenance program. Addictive Behaviors. 1977;2:9–14
  21. Tapert SF, Kilmer JR, Quigley LA, Larimer ME, Roberts LJ, Miller ET. Harm reduction strategies for illicit substance use and abuse. In:  Marlatt GA editors. Harm reduction: Pragmatic strategies for managing high-risk behaviors. New York, NY: The Guilford Press; 1998;p. 145–217
  22. WHO. (2004). WHO/UNODC/UNAIDS position paper: Substitution maintenance therapy in the management of opioid dependence and HIV/AIDS prevention. Geneva, Switzerland: Authors. Retrieved October 23, 2008, from http://www.who.int/substance_abuse/publications/en/PositionPaper_English.pdf.
  23. Willenbring ML, Hagedorn H, Postier A, Kenny M. Variations in evidence-based clinical practices in nine United States veterans administration opioid agonist therapy clinics. Drug and Alcohol Dependence. 2004;75:97–106
  24. Woody GE, Kane V, Lewis K, Thompson R. Premature deaths after discharge from methadone maintenance: A replication. Journal of Addiction Medicine. 2007;1(4):180–185

PII: S0955-3959(09)00043-7

doi: 10.1016/j.drugpo.2009.01.005

International Journal of Drug Policy
Volume 21, Issue 1 , Pages 82-85 , January 2010

Article Tools

* Image Usage & Resolution